Last $2.86 USD
Change Today +0.20 / 7.52%
Volume 36.0K
OCLS On Other Exchanges
Symbol
Exchange
OCLS is not on other exchanges.
As of 8:10 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

oculus innovative sciences i (OCLS) Snapshot

Open
$2.69
Previous Close
$2.66
Day High
$2.86
Day Low
$2.69
52 Week High
12/4/13 - $7.21
52 Week Low
11/21/13 - $2.20
Market Cap
24.2M
Average Volume 10 Days
49.1K
EPS TTM
$-0.35
Shares Outstanding
8.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OCULUS INNOVATIVE SCIENCES I (OCLS)

oculus innovative sciences i (OCLS) Related Bloomberg News

View More Bloomberg News

oculus innovative sciences i (OCLS) Related Businessweek News

No Related Businessweek News Found

oculus innovative sciences i (OCLS) Details

Oculus Innovative Sciences, Inc. designs, produces, and markets prescription and non-prescription products based on its Microcyn platform technology for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets in the United States, Mexico, Europe, and internationally. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of organisms that cause disease, including viruses, fungi, spores, and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, as well as Clostridium difficile, a highly contagious bacteria spread by human contact. It offers Microcyn-based human advanced wound and tissue care products as prescription and over-the-counter products; and Microcyn technology-based animal healthcare products under the Vetericyn brand. The company’s Microcyn has received eight 510(k) clearances for use as a medical device in wound care management, including for acute and chronic wounds, and in dermatology applications. In addition, it provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Oculus Innovative Sciences, Inc. sells its products directly, and through contract sales organization and distributors to hospitals, physicians, nurses, and other healthcare practitioners, as well as to dermatologists for the treatment of various skin afflictions. The company was formerly known as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in August 2001. Oculus Innovative Sciences, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.

31 Employees
Last Reported Date: 06/30/14
Founded in 1999

oculus innovative sciences i (OCLS) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $300.0K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $250.0K
Executive Vice President of International Ope...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

oculus innovative sciences i (OCLS) Key Developments

Oculus Innovative Sciences, Inc. Provides Earnings Guidance for the First Quarter Ending June 30, 2014

Oculus Innovative Sciences, Inc. provided earnings guidance for the first quarter ending June 30, 2014. For the quarter, the company expects negative or EBITDAS and had $1.7 million negative including Ruthigen expenses and $1.1 million without Ruthigen expenses. Total revenue to be in the range of $3.1 million.

Oculus Innovative Sciences, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Twelve Months Ended March 31, 2014

Oculus Innovative Sciences, Inc. announced unaudited consolidated earnings results for the fourth quarter and twelve months ended March 31, 2014. For the quarter, the company reported total revenues of $2.9 million, down $421,000, as compared to $3.3 million for the same period in the prior year. Loss from operations was $2,108,000 against $1,382,000 a year ago. Net income available to common shareholders was $7,457,000 against net loss available to common shareholders of $2,445,000 a year ago. Basic earnings per share were 1.00 cents against basic loss per share of 0.44 cents a year ago. LBITDAS was $1,698,000 against $1,107,000 a year ago. For the twelve months, the company reported total revenues of $13.7 million as compared to $15.5 million for the same period in the prior year. Loss from operations was $6,051 against $3,374,000 a year ago. Net income available to common shareholders was $3,735,000 against net loss available to common shareholders of $6,493,000 a year ago. Basic earnings per share were 0.54 cents against basic loss per share of 1.30 cents a year ago. LBITDAS was $4,316,000 against $1,505,000 a year ago.

Oculus Innovative Sciences, Inc. to Report Q4, 2014 Results on Jun 12, 2014

Oculus Innovative Sciences, Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Jun 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCLS:US $2.86 USD +0.20

OCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,411 JPY +7.00
Henry Schein Inc $118.11 USD +0.02
Integra LifeSciences Holdings Corp $47.74 USD +0.46
Patterson Cos Inc $39.57 USD +0.33
Smith & Nephew PLC 1,048 GBp +13.00
View Industry Companies
 

Industry Analysis

OCLS

Industry Average

Valuation OCLS Industry Range
Price/Earnings 4.9x
Price/Sales 1.5x
Price/Book 1.8x
Price/Cash Flow 6.0x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULUS INNOVATIVE SCIENCES I, please visit www.oculusis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.